NEFL and Alzheimer disease: The recent development of plasma biomarkers may help to elucidate if BPV might indeed contribute to AD pathology specifically, in addition to the known neuronal injury through vascular or other pathways, which could be measured with the unspecific biomarker neurofilament light chain (NfL) [10, 11].